26/10/2026
📰 NEWS: Nearly one third of patients with advanced melanoma saw tumours disappear completely after receiving TIL therapy plus pembrolizumab immunotherapy
In addition, approximately two thirds (62.5 per cent) of patients in the same group saw their tumours shrink significantly, with many experiencing substantial and long-lasting responses to the combined treatment.
These findings from the IOV-COM-202 clinical trial, an international, multicentre Phase II trial conducted at The Royal Marsden NHS Foundation Trust, were presented at the 2026 ESMO - European Society for Medical Oncology Congress by Dr Andrew Furness, Consultant Medical Oncologist and Solid Tumour Cellular Therapy Lead at The Royal Marsden NHS Foundation Trust and Leader of the Cellular Therapy and Translational Immunology Group at The Institute of Cancer Research, London.
Read more: https://oncologynewstoday.co.uk/nearly-one-third-of-patients-with-advanced-melanoma-saw-tumours-disappear-completely-after-receiving-til-therapy-plus-pembrolizumab-immunotherapy/
The Royal Marsden Cancer Charity
Results from a clinical trial have revealed nearly one third of patients with advanced melanoma saw their tumours disappear completely on...